Ncardia
1 known investors
Ncardia develops human induced pluripotent stem cell (iPSC) technology, offering iPSC-derived cell models, screening assays, and custom services to support drug, gene, and cell therapy development. It serves biopharma and therapeutic developers with tools for functional toxicity and cardiac safety testing.
BiotechDeep TechHealthtech
Investors · 1
Frequently asked questions
- What does Ncardia do?
- Ncardia develops human induced pluripotent stem cell (iPSC) technology, offering iPSC-derived cell models, screening assays, and custom services to support drug, gene, and cell therapy development. It serves biopharma and therapeutic developers with tools for functional toxicity and cardiac safety testing.
- Who are Ncardia's investors?
- Ncardia's investors include Vesalius Biocapital Partners.